Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $23.83, but opened at $22.08. Dyne Therapeutics shares last traded at $22.4380, with a volume of 1,955,620 shares traded.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on DYN shares. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, July 6th. Sanford C. Bernstein boosted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday. Finally, TD Cowen began coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.17.

Dyne Therapeutics Stock Down 6.9%

The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. The firm has a market capitalization of $3.67 billion, a P/E ratio of -6.89 and a beta of 1.06. The stock has a fifty day moving average price of $20.03 and a two-hundred day moving average price of $18.51.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period last year, the business earned ($1.05) EPS. Research analysts forecast that Dyne Therapeutics, Inc. will post -3.02 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the sale, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jason P. Rhodes sold 297,211 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director owned 2,962 shares in the company, valued at approximately $68,896.12. The trade was a 99.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders acquired 9,000 shares of company stock worth $156,800 and sold 2,277,428 shares worth $47,601,149. 9.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DYN. Creative Planning increased its stake in shares of Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after buying an additional 1,440 shares during the period. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics during the first quarter worth approximately $26,000. Caxton Associates LLP grew its holdings in Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.